Gw Pharmaceuticals Plc Ads (GWPH) 87.88 $GWPH
MJX Marijuana Index to Feature NYSE Distribution with 3 Unique Tickers; Fund Plans Registration in Q4 2014
ACCESSWIRE - 0 mins ago
Carlsbad, CA / ACCESSWIRE / Aug 21, 2014 / MJX is pleased to announce that http://www.marijuanaindex.org/ (MJX Marijuana Index) has been acquired by MJX Ventures, Inc.http://www.mjxfund.com/. Through a new partnership with Interactive Data, a global leader in asset valuations, data, and index management, the MJX Marijuana Index will now feature three unique NYSE tickers with distribution on NYSE's index system.
Is This the End of Medical Marijuana?
Sean Williams, The Motley Fool - Motley Fool - Sun Sep 14, 12:17PM CDT
Source: GW Pharmaceuticals. Marijuana perception among U.S. citizens is rapidly changing. For the first time ever last year, according to a poll from Gallup , more respondents were in favor of legalizing marijuana than were opposed to its...
Is Medical Marijuana Destined to Become a Top Schizophrenia Treatment?
Todd Campbell, The Motley Fool - Motley Fool - Sat Sep 13, 12:07PM CDT
Source: GW Pharmaceuticals. One of the most contentious debates surrounding medical marijuana is whether its use could help millions of people suffering from schizophrenia. For decades, the conventional wisdom has been that marijuana, at a minimum,...
Off the Charts
at The Street - Fri Sep 05, 2:31PM CDT
9/02/14: Baidu BIDU exploded to the upside today and hit our stop price at $222. We are removing it from our short ideas list with a loss of 3.38%.
Is It Time to Buy Shares in This Marijuana Stock?
Todd Campbell, The Motley Fool - Motley Fool - Fri Sep 05, 7:48AM CDT
Marijuana drugmaker GW Pharmaceuticals Plc shares have returned an unbelievable 500% in the past year; trouncing the S&P 500 ETFs 23% return and handily outpacing the 37% return for the iShares Nasdaq Biotechnology ETF. Given GW Pharma's...
BreedIT, Monsanto and GW Pharma Underscoring Advancements in Medical Marijuana Industry
ACCESSWIRE - Thu Sep 04, 8:29AM CDT
Whitefish, MT / September 4, 2014 / There is no shortage of philosophies coming from so-called pundits on how to play the legalized marijuana movement. The problem is that it's a nascent industry full of nascent companies, making it difficult to discern which companies will prevail. Many jumping into the pot space are throwing a dart of momentum plays (mostly those in the competitive growing or retail businesses) with only a modicum of information. There are some sectors that are being somewhat overlooked that may offer a more fundamentally sound opportunity for growth. The biotech space is like stacking speculation (biotech) on top of risk (medical marijuana), but that usually adds up to a home run if a company can get it right. Most investors are aware of the potential regulatory hurdles, but that has not steered them away from GW Pharmaceuticals (NASDAQ: GWPH). Probably the best biotech working with cannibinoids, GW Pharma has caught the attention of Wall Street for many reasons, including an upcoming clinical trial for Dravet syndrome, a terrible, life-threatening disease where patients are plagued with seizures that many families argue cannabis provides relief (if not essentially a cure).
5 Things That Marijuana Stock GW Pharmaceuticals plc's Management Wants You To Know
Todd Campbell, The Motley Fool - Motley Fool - Thu Aug 28, 3:54PM CDT
Few areas have been as intriguing to investors this year as medical marijuana. The approval of legislation allowing its use in states such as Colorado has kicked off a flurry of commentary regarding the good and bad of marijuana use. That increased...
NTRR Builds Cannabis Network and Expertise at Major Washington Conventions
Business Wire - Thu Aug 28, 4:00AM CDT
Neutra Corp. (OTCBB: NTRR) made big progress in its mission to build a nationwide network of cannabis-related business partners this month when representatives from the company spoke to retailers, distributors and customers at two major cannabis conventions in the state of Washington.
GW Pharmaceuticals to Present at Upcoming Investor Conferences
GlobeNewswire - Thu Aug 28, 1:00AM CDT
GW Pharmaceuticals plc (Nasdaq:GWPH) (AIM:GWP) ("GW," "the Company" or "the Group"
, a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announced that Justin Gover, GW's Chief Executive Officer, is scheduled to present at the Morgan Stanley Global Healthcare Conference at the Grand Hyatt in New York City on Monday, 8 September 2014 at 12:50 p.m. ET and at the Bank of America Merrill Lynch Global Healthcare Conference at the Bank of America Merrill Lynch Financial Centre in London on Wednesday, 17 September at 11:25 a.m. BST.
*UPDATE* Big Pharma And Medical Marijuana; How Can They Coexist?
ACCESSWIRE - Mon Aug 25, 9:04AM CDT
New York, NY / ACCESSWIRE / August, 25, 2014 / Everyone has been closely following the marijuana industry. Anywhere from accessories from companies like Vapor Group Inc. (OTCQB:VPOR) to actual growing operations, this market has been a hotbed for analysis and speculation. Of course as with many developing sectors, marijuana has a long way to go before we start hearing about FDA approvals and big business taking a stand. What we have seen thus far, however, is the emergence of brand new companies mostly trading on the OTC who are becoming the mavericks of the MJ marketplace and possibly leading the way for big business and more importantly, Big Pharma to follow.
OrganiGram Begins Trading as MMPR Licensed Producer
ACCESSWIRE - Mon Aug 25, 8:28AM CDT
WHITEFISH, MT / August 25, 2014 / Organigram Inc. (TSX-V: OGI) became the latest publicly traded licensed producer under Canada's Marihuana for Medical Purposes Regulations ("MMPR" , following in the footsteps of companies like Tweed Inc. (TSX-V: TWD) (OTC: TWMJF). After completing its reverse merger and a mandatory trading halt, investors can now purchase the stock under the ticker symbol "OGI".
GreenLeaf Acquisition Expands Endexx's Product Line Up
ACCESSWIRE - Mon Aug 25, 8:23AM CDT
WHITEFISH, MT / August 25, 2014 / The market for legalized marijuana in the United States is expected to surpass $8 billion by 2018, according to Marijuana Business Daily. In addition to the recreational legalization of marijuana in Colorado and Washington State, voters will have the opportunity to legalize the drug in Washington DC, Alaska and Oregon in November, which could potentially expand the market far beyond the $8 billion figure.
3 Reasons Why Marijuana Stock GW Pharmaceuticals Could Fall
Todd Campbell, The Motley Fool - Motley Fool - Thu Aug 21, 3:53PM CDT
Investors often find that turning a blind eye to risks lurking in their investments is far from a profit-friendly strategy. Identifying long-term stocks to hold in portfolios means understanding both a company's puts and takes. That balanced...
Easton and GW Pharmaceuticals Lead Cannabis Stocks Higher Last Week
ACCESSWIRE - Tue Aug 19, 9:02AM CDT
WHITEFISH, MT / ACCESSWIRE / August 19, 2014 / The Marijuana Index(TM) moved marginally higher last week, driven by a 7.71% rise in GW Pharmaceuticals plc (NASDAQ: GWPH) shares, which was partially offset by a 15.3% drop in Medbox Inc. (OTC: MDBX) shares.
A New Cannabinoid-based Arthritis Therapy in the Making
ACCESSWIRE - Tue Aug 19, 8:50AM CDT
WHITEFISH, MT / August 19, 2014 / Cannabinoids have been the focus of intense clinical research following the legalization of medical cannabis by several U.S. states. While pioneers like British-based GW Pharmaceuticals plc (NASDAQ: GWPH) have been actively studying cannabinoids since the 1990s, many North American companies haven't started major research until recent years with compounds just starting clinical trials.
Small Business Operations to Large Scale Companies Take Steps to Increase Security Surveillance - Company Selected for Comprehensive Cannabis Security System Installation
PR Newswire - Thu Aug 14, 8:05AM CDT
Security and Surveillance needs become top priority in Cannabis / Legal Marijuana industry as sector continues expansion and growth for the following emerging companies: DirectView Holdings, Inc. (OTC: DIRV), Nuvilex, Inc. (OTC: NVLX), GW Pharmaceuticals plc (NASDAQ: GWPH), Singlepoint, Inc. (OTC: SING) and Cannabis Science, Inc. (CBIS).
NTRR Leadership Plans Overseas Trip to Source New Product Suppliers
Business Wire - Thu Aug 14, 4:00AM CDT
Neutra Corp.'s (OTCBB: NTRR) executive leadership will travel overseas in the near future to source new products for its business model and make final preparations for the impending production of its new Diamond Anvil vapor pen.
Vape Holdings & Terra Tech Were Top Cannabis Stock Gainers Last Week
ACCESSWIRE - Tue Aug 12, 8:47AM CDT
WHITEFISH, MT / August 12, 2014 / The Marijuana Index(TM) moved lower last week, as bellwethers GW Pharmaceuticals plc (NASDAQ: GWPH) and MedBox Inc. (OTC: MDBX) fell 0.8% and 14%, respectively, alongside many other smaller industry components.
NTRR: New Product Wows Distributors at Massive Las Vegas Trade Show
Business Wire - Tue Aug 12, 3:54AM CDT
Neutra Corp. (OTCBB: NTRR) wowed distributors last week at one of the world's largest retail trade shows with its new Diamond Anvil vaporizer pen, an innovative new product being readied for release.
Cannabis Should Be Treated as an Agricultural Commodity, Not a Biotech Investment
ACCESSWIRE - Mon Aug 11, 1:44PM CDT
Pittsburgh, PA / August 11, 2014 / While the future of cannabusiness is certainly bright, one controversial yet crucial caveat must be made. Pot stocks should be treated as an agricultural commodity investment rather than as a biotech investment. This is not to say that cannabis cannot be used as a pharmaceutical. It certainly can. Rather it should not be invested in as one would invest in a pharmaceutical. Taking a biotech strategy with pot stocks is the wrong road to take.
MJX Marijuana Index to Feature NYSE Distribution with 3 Unique Tickers; Fund Plans Registration in Q4 2014
ACCESSWIRE - 0 mins ago
Carlsbad, CA / ACCESSWIRE / Aug 21, 2014 / MJX is pleased to announce that http://www.marijuanaindex.org/ (MJX Marijuana Index) has been acquired by MJX Ventures, Inc.http://www.mjxfund.com/. Through a new partnership with Interactive Data, a global leader in asset valuations, data, and index management, the MJX Marijuana Index will now feature three unique NYSE tickers with distribution on NYSE's index system.
Is This the End of Medical Marijuana?
Sean Williams, The Motley Fool - Motley Fool - Sun Sep 14, 12:17PM CDT
Source: GW Pharmaceuticals. Marijuana perception among U.S. citizens is rapidly changing. For the first time ever last year, according to a poll from Gallup , more respondents were in favor of legalizing marijuana than were opposed to its...
Is Medical Marijuana Destined to Become a Top Schizophrenia Treatment?
Todd Campbell, The Motley Fool - Motley Fool - Sat Sep 13, 12:07PM CDT
Source: GW Pharmaceuticals. One of the most contentious debates surrounding medical marijuana is whether its use could help millions of people suffering from schizophrenia. For decades, the conventional wisdom has been that marijuana, at a minimum,...
Off the Charts
at The Street - Fri Sep 05, 2:31PM CDT
9/02/14: Baidu BIDU exploded to the upside today and hit our stop price at $222. We are removing it from our short ideas list with a loss of 3.38%.
Is It Time to Buy Shares in This Marijuana Stock?
Todd Campbell, The Motley Fool - Motley Fool - Fri Sep 05, 7:48AM CDT
Marijuana drugmaker GW Pharmaceuticals Plc shares have returned an unbelievable 500% in the past year; trouncing the S&P 500 ETFs 23% return and handily outpacing the 37% return for the iShares Nasdaq Biotechnology ETF. Given GW Pharma's...
BreedIT, Monsanto and GW Pharma Underscoring Advancements in Medical Marijuana Industry
ACCESSWIRE - Thu Sep 04, 8:29AM CDT
Whitefish, MT / September 4, 2014 / There is no shortage of philosophies coming from so-called pundits on how to play the legalized marijuana movement. The problem is that it's a nascent industry full of nascent companies, making it difficult to discern which companies will prevail. Many jumping into the pot space are throwing a dart of momentum plays (mostly those in the competitive growing or retail businesses) with only a modicum of information. There are some sectors that are being somewhat overlooked that may offer a more fundamentally sound opportunity for growth. The biotech space is like stacking speculation (biotech) on top of risk (medical marijuana), but that usually adds up to a home run if a company can get it right. Most investors are aware of the potential regulatory hurdles, but that has not steered them away from GW Pharmaceuticals (NASDAQ: GWPH). Probably the best biotech working with cannibinoids, GW Pharma has caught the attention of Wall Street for many reasons, including an upcoming clinical trial for Dravet syndrome, a terrible, life-threatening disease where patients are plagued with seizures that many families argue cannabis provides relief (if not essentially a cure).
5 Things That Marijuana Stock GW Pharmaceuticals plc's Management Wants You To Know
Todd Campbell, The Motley Fool - Motley Fool - Thu Aug 28, 3:54PM CDT
Few areas have been as intriguing to investors this year as medical marijuana. The approval of legislation allowing its use in states such as Colorado has kicked off a flurry of commentary regarding the good and bad of marijuana use. That increased...
NTRR Builds Cannabis Network and Expertise at Major Washington Conventions
Business Wire - Thu Aug 28, 4:00AM CDT
Neutra Corp. (OTCBB: NTRR) made big progress in its mission to build a nationwide network of cannabis-related business partners this month when representatives from the company spoke to retailers, distributors and customers at two major cannabis conventions in the state of Washington.
GW Pharmaceuticals to Present at Upcoming Investor Conferences
GlobeNewswire - Thu Aug 28, 1:00AM CDT
GW Pharmaceuticals plc (Nasdaq:GWPH) (AIM:GWP) ("GW," "the Company" or "the Group"
, a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announced that Justin Gover, GW's Chief Executive Officer, is scheduled to present at the Morgan Stanley Global Healthcare Conference at the Grand Hyatt in New York City on Monday, 8 September 2014 at 12:50 p.m. ET and at the Bank of America Merrill Lynch Global Healthcare Conference at the Bank of America Merrill Lynch Financial Centre in London on Wednesday, 17 September at 11:25 a.m. BST. *UPDATE* Big Pharma And Medical Marijuana; How Can They Coexist?
ACCESSWIRE - Mon Aug 25, 9:04AM CDT
New York, NY / ACCESSWIRE / August, 25, 2014 / Everyone has been closely following the marijuana industry. Anywhere from accessories from companies like Vapor Group Inc. (OTCQB:VPOR) to actual growing operations, this market has been a hotbed for analysis and speculation. Of course as with many developing sectors, marijuana has a long way to go before we start hearing about FDA approvals and big business taking a stand. What we have seen thus far, however, is the emergence of brand new companies mostly trading on the OTC who are becoming the mavericks of the MJ marketplace and possibly leading the way for big business and more importantly, Big Pharma to follow.
OrganiGram Begins Trading as MMPR Licensed Producer
ACCESSWIRE - Mon Aug 25, 8:28AM CDT
WHITEFISH, MT / August 25, 2014 / Organigram Inc. (TSX-V: OGI) became the latest publicly traded licensed producer under Canada's Marihuana for Medical Purposes Regulations ("MMPR"
, following in the footsteps of companies like Tweed Inc. (TSX-V: TWD) (OTC: TWMJF). After completing its reverse merger and a mandatory trading halt, investors can now purchase the stock under the ticker symbol "OGI". GreenLeaf Acquisition Expands Endexx's Product Line Up
ACCESSWIRE - Mon Aug 25, 8:23AM CDT
WHITEFISH, MT / August 25, 2014 / The market for legalized marijuana in the United States is expected to surpass $8 billion by 2018, according to Marijuana Business Daily. In addition to the recreational legalization of marijuana in Colorado and Washington State, voters will have the opportunity to legalize the drug in Washington DC, Alaska and Oregon in November, which could potentially expand the market far beyond the $8 billion figure.
3 Reasons Why Marijuana Stock GW Pharmaceuticals Could Fall
Todd Campbell, The Motley Fool - Motley Fool - Thu Aug 21, 3:53PM CDT
Investors often find that turning a blind eye to risks lurking in their investments is far from a profit-friendly strategy. Identifying long-term stocks to hold in portfolios means understanding both a company's puts and takes. That balanced...
Easton and GW Pharmaceuticals Lead Cannabis Stocks Higher Last Week
ACCESSWIRE - Tue Aug 19, 9:02AM CDT
WHITEFISH, MT / ACCESSWIRE / August 19, 2014 / The Marijuana Index(TM) moved marginally higher last week, driven by a 7.71% rise in GW Pharmaceuticals plc (NASDAQ: GWPH) shares, which was partially offset by a 15.3% drop in Medbox Inc. (OTC: MDBX) shares.
A New Cannabinoid-based Arthritis Therapy in the Making
ACCESSWIRE - Tue Aug 19, 8:50AM CDT
WHITEFISH, MT / August 19, 2014 / Cannabinoids have been the focus of intense clinical research following the legalization of medical cannabis by several U.S. states. While pioneers like British-based GW Pharmaceuticals plc (NASDAQ: GWPH) have been actively studying cannabinoids since the 1990s, many North American companies haven't started major research until recent years with compounds just starting clinical trials.
Small Business Operations to Large Scale Companies Take Steps to Increase Security Surveillance - Company Selected for Comprehensive Cannabis Security System Installation
PR Newswire - Thu Aug 14, 8:05AM CDT
Security and Surveillance needs become top priority in Cannabis / Legal Marijuana industry as sector continues expansion and growth for the following emerging companies: DirectView Holdings, Inc. (OTC: DIRV), Nuvilex, Inc. (OTC: NVLX), GW Pharmaceuticals plc (NASDAQ: GWPH), Singlepoint, Inc. (OTC: SING) and Cannabis Science, Inc. (CBIS).
NTRR Leadership Plans Overseas Trip to Source New Product Suppliers
Business Wire - Thu Aug 14, 4:00AM CDT
Neutra Corp.'s (OTCBB: NTRR) executive leadership will travel overseas in the near future to source new products for its business model and make final preparations for the impending production of its new Diamond Anvil vapor pen.
Vape Holdings & Terra Tech Were Top Cannabis Stock Gainers Last Week
ACCESSWIRE - Tue Aug 12, 8:47AM CDT
WHITEFISH, MT / August 12, 2014 / The Marijuana Index(TM) moved lower last week, as bellwethers GW Pharmaceuticals plc (NASDAQ: GWPH) and MedBox Inc. (OTC: MDBX) fell 0.8% and 14%, respectively, alongside many other smaller industry components.
NTRR: New Product Wows Distributors at Massive Las Vegas Trade Show
Business Wire - Tue Aug 12, 3:54AM CDT
Neutra Corp. (OTCBB: NTRR) wowed distributors last week at one of the world's largest retail trade shows with its new Diamond Anvil vaporizer pen, an innovative new product being readied for release.
Cannabis Should Be Treated as an Agricultural Commodity, Not a Biotech Investment
ACCESSWIRE - Mon Aug 11, 1:44PM CDT
Pittsburgh, PA / August 11, 2014 / While the future of cannabusiness is certainly bright, one controversial yet crucial caveat must be made. Pot stocks should be treated as an agricultural commodity investment rather than as a biotech investment. This is not to say that cannabis cannot be used as a pharmaceutical. It certainly can. Rather it should not be invested in as one would invest in a pharmaceutical. Taking a biotech strategy with pot stocks is the wrong road to take.
